Shinmura K, Bennett R A, Tarapore P, Fukasawa K
Department of Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Oncogene. 2007 May 3;26(20):2939-44. doi: 10.1038/sj.onc.1210085. Epub 2006 Oct 30.
Abnormal amplification of centrosomes is the major cause of mitotic defects and chromosome instability in cancer cells. Centrosomes duplicate once in each cell cycle, and abrogation of the regulatory mechanism underlying centrosome duplication leads to centrosome amplification. p53 tumor suppressor protein is involved in the regulation of centrosome duplication: loss of p53 as well as expression of certain p53 mutants result in deregulated centrosome duplication and centrosome amplification. p53 at least in part depends on its transactivation function to control centrosome duplication, primarily via upregulation of p21 cyclin-dependent kinase (CDK) inhibitor, which prevents untimely activation of CDK2/cyclin E, a key initiator of centrosome duplication. However, numerous studies have shown the presence of p53 at centrosomes, yet the role of the centrosomally localized p53 in the regulation of centrosome duplication had been enigmatic. Here, we comparatively examined wild-type p53 and p53 mutants that are transactivation(+)/centrosome-binding(-), transactivation(-)/centrosome-binding(+) and transactivation(-)/centrosome-binding(-) for their abilities to control centrosome duplication. We found that the transactivation(+)/centrosome-binding(-) and transactivation(-)/centrosome-binding(+) mutants suppress centrosome duplication only partially compared with wild-type p53. Moreover, the transactivation(-)/centrosome-binding(-) mutant almost completely lost the ability to suppress centrosome duplication. These observations provide direct evidence for the centrosomally localized p53 to participate in the regulation of centrosome duplication in a manner independent of its transactivation function in addition to its transactivation-dependent regulation of centrosome duplication.
中心体的异常扩增是癌细胞有丝分裂缺陷和染色体不稳定的主要原因。中心体在每个细胞周期中复制一次,而中心体复制调控机制的缺失会导致中心体扩增。p53肿瘤抑制蛋白参与中心体复制的调控:p53缺失以及某些p53突变体的表达会导致中心体复制失控和中心体扩增。p53至少部分依赖其反式激活功能来控制中心体复制,主要是通过上调p21细胞周期蛋白依赖性激酶(CDK)抑制剂,从而防止细胞周期蛋白依赖性激酶2/细胞周期蛋白E(CDK2/cyclin E)过早激活,而CDK2/cyclin E是中心体复制的关键启动因子。然而,大量研究表明中心体上存在p53,但中心体定位的p53在中心体复制调控中的作用一直是个谜。在这里,我们比较研究了野生型p53以及反式激活(+)/中心体结合(-)、反式激活(-)/中心体结合(+)和反式激活(-)/中心体结合(-)的p53突变体控制中心体复制的能力。我们发现,与野生型p53相比,反式激活(+)/中心体结合(-)和反式激活(-)/中心体结合(+)突变体只能部分抑制中心体复制。此外,反式激活(-)/中心体结合(-)突变体几乎完全丧失了抑制中心体复制的能力。这些观察结果提供了直接证据,表明中心体定位的p53除了通过其反式激活依赖的方式调控中心体复制外,还以一种独立于其反式激活功能的方式参与中心体复制的调控。